Home > > > > > Report Detail

Investigation Report on China’s Montelukast Market, 2018-2022

Publisher Name :
Date: 29-Nov-2018
No. of pages: 30

More than 300 million people in the world are suffering from seasonal asthma of varying degrees. The number is higher in countries with severe environmental pollution and high tobacco consumption. Asthma and allergic rhinitis are common nowadays. Owing to heavy air pollution, the incidences of these diseases are increasing year by year.

Montelukast, developed by MSD, is widely used in the treatment of allergic rhinitis and asthma. As a selective leukotriene D4 receptor antagonist, it selectively binds to the leukotrienes in the airway, blocks the action of allergic mediators, reduces airway inflammation, and makes the airway unobstructed. In 1998, Montelukast sodium tablets (10 mg) and chewable tablets (5 mg) were approved by the FDA and first marketed in the U.S. in the trade name of “Singulair”. In 2000 and 2002, Montelukast chewable tablets (4 mg) and granules (4 mg) were approved for sale, mainly for the prevention and long-term treatment of asthma in adults and children aged above 2.

In 1999, MSD’s Montelukast chewable tablets (5mg) and tablets (10mg) were approved to enter China in the trade name of “Singulair”, followed by Montelukast chewable tablets (4mg) and granules (4mg). In 2006, the generic Montelukast tablets (10mg) and chewable tablets (5mg) by Sichuan Otsuka Pharmaceutical Co., Ltd. were approved to be sold in the trade name of “Bystine”. Many other companies in China have also filed applications for generic Montelukast.

According to CRI’s market research, from 2005 to 2010, the annual sales value of Montelukast in China grew at a CAGR of more than 40%. As competing products emerged, the growth rate slowed down from 2011 but stays above 10%. In 2017, the market size of Montelukast was about CNY 552 million. The market was dominated by MSD, Lunan Better Pharmaceutical Co., Ltd., and Sichuan Otsuka Pharmaceutical Co., Ltd. Declining in recent years, the market share by sales value of MSD was close to 73%.

According to statistics, there are more than 30 million asthma patients and 300 million to 400 million patients with allergic rhinitis in China. And the numbers will continue to rise with increasingly serious environmental pollution. In China, Montelukast is considered as one of the best anti-asthmatic drugs, which promises huge market potential.

Topics Covered:


  • Situation of respiratory diseases in China

  • Supply and sales of Montelukast in China

  • Prices of Montelukast in China

  • Competition on China’s Montelukast market

  • Market share of Montelukast manufacturers in China

  • Prospect of China’s Montelukast Market, 2018-2022

Investigation Report on China’s Montelukast Market, 2018-2022

Table of Contents

1 Basic Concept of Montelukast
1.1 Indications for Montelukast
1.2 Development of Montelukast in China
1.3 Government Approval of Montelukast in China

2 Sales of Montelukast in China, 2013-2017
2.1 Sales Value of Montelukast
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Montelukast
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Montelukast by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Granules

3 Analysis on Major Montelukast Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Montelukast Manufacturers 3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 MSD
3.2.1 Enterprise Profile
3.2.2 Sales of MSD’s Montelukast in China
3.3 Lunan Better Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Lunan Better Pharmaceutical Co., Ltd.’s Montelukast in China
3.4 Sichuan Otsuka Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Sichuan Otsuka Pharmaceutical Co., Ltd.’s Montelukast in China

4 Prices of Montelukast in China, 2017-2018
4.1 MSD (Singulair)
4.2 Lunan Better Pharmaceutical Co., Ltd. (Pingqi)
4.3 Sichuan Otsuka Pharmaceutical Co., Ltd. (Bystine)

5 Prospect of China’s Montelukast Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

List of Charts

Chart Governmental Approval of Montelukast in China
Chart Sales Value of Montelukast in China, 2013-2017
Chart Sales Value of Montelukast in Parts of China, 2013-2017
Chart Sales Volume of Montelukast in China, 2013-2017
Chart Sales Volume of Montelukast in Parts of China, 2013-2017
Chart Sales Value of Montelukast Tablets in China, 2013-2017
Chart Sales Value of Montelukast Granules in China, 2013-2017
Chart Market Share by Sales Value of Top 3 Montelukast Manufacturers, 2013-2017
Chart Market Share by Sales Volume of Top 3 Montelukast Manufacturers, 2013-2017
Chart Sales Value of MSD’s Montelukast, 2013-2017
Chart Sales Volume of MSD’s Montelukast, 2013-2017
Chart Sales Value of Lunan Better Pharmaceutical Co., Ltd.’s Montelukast, 2013-2017
Chart Sales Volume of Lunan Better Pharmaceutical Co., Ltd.’s Montelukast, 2013-2017
Chart Sales Value of Sichuan Otsuka Pharmaceutical Co., Ltd.’s Montelukast, 2013-2017
Chart Sales Volume of Sichuan Otsuka Pharmaceutical Co., Ltd.’s Montelukast, 2013-2017
Chart Prices of MSD’s Montelukast in Parts of China, 2017-2018
Chart Prices of Lunan Better Pharmaceutical Co., Ltd.’s Montelukast in Parts of China, 2017-2018
Chart Prices of Sichuan Otsuka Pharmaceutical Co., Ltd.’s Montelukast in Parts of China, 2017-2018
Chart Forecast on Sales Volume of Montelukast in China, 2018-2022

  • Global Montelukast Sodium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 134
    According to our LPI (LP Information) latest study, the global Montelukast Sodium market size was valued at US$ 336.3 million in 2023. With growing demand in downstream market, the Montelukast Sodium is forecast to a readjusted size of US$ 815.4 million by 2030 with a CAGR of 13.5% during review period. The research report highlights the growth potential of the global Montelukast Sodium market. Montelukast Sodium are expected to show stable growth in the future market. However, product d......
  • Global Montelukast Sodium Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 132
    According to our (Global Info Research) latest study, the global Montelukast Sodium market size was valued at USD 353.8 million in 2023 and is forecast to a readjusted size of USD 803.8 million by 2030 with a CAGR of 12.4% during review period. Montelukast sodium is a hygroscopic, optically active, and white to off-white powder. Montelukast sodium is freely soluble in ethanol, methanol, and water and practically insoluble in acetonitrile. It is administered orally for prophylaxis and chr......
  • Asthma Therapeutics - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 114
    The global Asthma Therapeutics market size is expected to reach US$ 27800 million by 2029, growing at a CAGR of 3.3% from 2023 to 2029. The market is mainly driven by the significant applications of Asthma Therapeutics in various end use industries. The expanding demands from the Hospitals and Clinics, are propelling Asthma Therapeutics market. Inhalation, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in......
  • Global Asthma Therapeutics Market Research Report 2023, Forecast to 2028
    Published: 15-Dec-2023        Price: US 2680 Onwards        Pages: 163
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Budesonide Aerosol Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 146
    Report Overview: The Global Budesonide Aerosol Market Size was estimated at USD 7996.70 million in 2022 and is projected to reach USD 41912.84 million by 2029, exhibiting a CAGR of 26.70% during the forecast period. This report provides a deep insight into the global Budesonide Aerosol market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key marke......
  • Global Asthma Therapeutics Professional Survey Report 2023, Forecast to 2028
    Published: 15-Dec-2023        Price: US 3280 Onwards        Pages: 139
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • Global Montelukast Sodium Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 144
    Report Overview: Montelukast sodium is a hygroscopic, optically active, and white to off-white powder. Montelukast sodium is freely soluble in ethanol, methanol, and water and practically insoluble in acetonitrile. It is administered orally for prophylaxis and chronic treatment of asthma, exercise-induced bronchoconstriction, and allergic rhinitis. The Global Montelukast Sodium Market Size was estimated at USD 816.70 million in 2022 and is projected to reach USD 1921.37 million by 20......
  • Global Doxofylline (API) Market Research Report 2023
    Published: 28-Nov-2023        Price: US 2900 Onwards        Pages: 88
    Doxofylline (also known as doxophylline) is a phosphodiesterase inhibiting bronchodilator used in The treatment of chronic respiratory diseases such as asthma and COPD. Like theophylline, it is a xanthine derivative. According to QYResearch's new survey, global Doxofylline (API) market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with The CAGR of % during The period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Uk......
  • Global Montelukast Sodium Market Research Report 2023, Forecast to 2028
    Published: 21-Nov-2023        Price: US 2680 Onwards        Pages: 164
    Montelukast sodium is an organic sodium salt. Montelukast is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This ......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs